Metastatic breast cancer (MBC) occurs in 20–30% of women with breast cancer and is an
incurable disease. Treatment is palliative and directed to prolong survival, decrease …

Purpose To investigate the performance of tumor subtype and various magnetic resonance
(MR) imaging parameters in the assessment of tumor response to neoadjuvant systemic …

Background The concept of metronomic chronic administration of low-dose chemotherapy
has become relevant for the treatment of cancer in the last several years. This study sought …

This study aimed to investigate the antitumor and antiangiogenic effects utilizing a novel
therapy regimen of metronomic topotecan and pazopanib, a multireceptor tyrosine kinase …

Purpose: Most primary human ovarian tumors and peritoneal implants, as well as tumor
vascular endothelial cells, express the CD44 family of cell surface proteoglycans, the natural …

A vascular endothelial growth factor (VEGF) inhibitor might enhance metronomic
chemotherapy in previously treated metastatic breast cancer (MBC) patients. Anthra-cycline …

Background Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly
prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have …

Nonsmall‐cell lung cancer (NSCLC) is not generally a chemosensitive tumor, and the
mechanism of resistance to the relevant anticancer drugs has not been fully elucidated …

The effects of breast cancer conventional chemotherapy on tumor angiogenesis need to be
further characterized. Neoadjuvant chemotherapy is an ideal model to evaluate the results of …

Purpose: Metronomic chemotherapy regimens have shown anti-tumor activity by anti-
angiogenic mechanisms, however, the efficacy of metronomic topotecan in ovarian cancer is …